Search results for "IBA"

showing 10 items of 1355 documents

Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double-Blinded Placebo-Controlled Trial

2007

Early steroid withdrawal after liver transplantation (LT) is desirable in order to reduce steroid side effects. Between February 2000 and August 2004, 110 patients after LT were included in this prospective, randomized, double-blind, placebo-controlled trial. Randomization was performed before LT. In all patients, tacrolimus was used without induction therapy. All patients received methylprednisolon for 14 days, thereafter a double-blinded medication containing either placebo (n = 56) or methylprednisolon (n = 54) for 6 months, which was completely stopped thereafter. End points were patient and graft survival, acute and chronic rejection, and incidence of steroid side effects during the fi…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsRandomizationmedicine.drug_classmedicine.medical_treatmentPlacebo-controlled studyLiver transplantationPlaceboMethylprednisoloneGastroenterologyTacrolimuslaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Antibacterial agentTransplantationbusiness.industryMiddle AgedTacrolimusLiver TransplantationSurgeryCorticosteroidFemaleSafetybusinessImmunosuppressive AgentsFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial

2016

Background Preterm delivery is a leading cause of neonatal morbidity and death. It often results from chorioamnionitis, which is a complication of bacterial vaginosis. Probiotics are effective in the treatment of bacterial vaginosis in women who were not pregnant; studies in pregnant woman are missing. Objective The purpose of this study was to evaluate whether an oral probiotic food supplement supports the maintenance or restoration of a normal vaginal microbiota during pregnancy. Study Design We conducted a randomized, placebo-controlled, triple-blind, parallel group trial. Oral Lactobacillus rhamnosus GR-1and L reuteri RC-14 (10 9 colony-forming units) or placebo were administered for 8 …

AdultLimosilactobacillus reuterimedicine.medical_specialtyAdministration OralChorioamnionitisPlacebolaw.inventionYoung Adult03 medical and health sciencesProbiotic0302 clinical medicineLactobacillus rhamnosusRandomized controlled trialPregnancylawmedicineHumans030212 general & internal medicinePregnancy030219 obstetrics & reproductive medicinebiologyLacticaseibacillus rhamnosusObstetricsbusiness.industryMicrobiotaProbioticsObstetrics and GynecologyMiddle Agedbiology.organism_classificationmedicine.diseasePregnancy Trimester Firstmedicine.anatomical_structureVaginaVaginaFemaleBacterial vaginosisbusinessAmerican Journal of Obstetrics and Gynecology
researchProduct

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin…

2010

EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C and significant fibrosis who previously failed any interferon-alfa/ribavirin therapy. The aim of the present study was to assess FibroTest (FT), a validated non-invasive marker of fibrosis in treatment-naive patients, as a possible alternative to biopsy as the baseline predictor of subsequent early virologic (EVR) and sustained virologic response (SVR) in previously treated patients.Of 2312 patients enrolled, 1459 had an available baseline FT, biopsy, and complete data. Uni- (UV) and multi-variable (MV) analyses were performed us…

AdultLiver CirrhosisMaleBiopsyFibrotestInterferon-alphaAlanine TransaminaseHepatitis C ChronicInterferon alpha-2Middle AgedPrognosisRecombinant ProteinsPolyethylene GlycolsFatty LiverRibavirinHumansDrug Therapy CombinationFemaleProspective Studies
researchProduct

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

2015

ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

AdultLiver CirrhosisMaleDaclatasvirPyrrolidinesAlpha interferonHIV InfectionsHepacivirusPharmacologyAntiviral AgentsRaltegravir PotassiumPolyethylene Glycolschemistry.chemical_compoundPharmacokineticsRaltegravir PotassiumRibavirinMedicineHumansPharmacology (medical)PharmacologySulfonamidesbusiness.industryCoinfectionRibavirinImidazolesvirus diseasesInterferon-alphaValineHepatitis CHepatitis C ChronicMiddle AgedRaltegravirmedicine.diseaseIsoquinolinesdigestive system diseasesRecombinant ProteinsInfectious DiseaseschemistryLiverHIV-1AsunaprevirDrug Therapy CombinationFemaleCarbamatesbusinessmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

2007

Aims To assess whether host metabolic factors influence the degree of hepatic steatosis and fibrosis in patients infected with hepatitis C virus, and to evaluate the impact of anti-viral therapy on insulin resistance and serum levels of adipocytokines. Methods Clinical and biochemical features, anthropometrical characteristics, and levels of fasting insulin, leptin, adiponectin and resistin were measured in ‘naı¨ve’ patients with chronic hepatitis C, before, during and after therapy with Peg-Interferon-alpha 2a plus Ribavirin. Results Forty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years; 62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2 , and visceral obesity was present in 24…

AdultLiver CirrhosisMaleInterferon-alphahcv steatosisHepatitis C ChronicInterferon alpha-2Intra-Abdominal FatMiddle AgedAntiviral AgentsRecombinant ProteinsFatty LiverRibavirinAdipocytesHumansFemaleObesityInsulin ResistanceAlimentary pharmacologytherapeutics
researchProduct

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C

2010

UNLABELLED 25-Hydroxyvitamin D (25[OH]D) can potentially interfere with inflammatory response and fibrogenesis. Its role in disease progression in chronic hepatitis C (CHC) and its relation with histological and sustained virological response (SVR) to therapy are unknown. One hundred ninety-seven patients with biopsy-proven genotype 1 (G1) CHC and 49 healthy subjects matched by age and sex were consecutively evaluated. One hundred sixty-seven patients underwent antiviral therapy with pegylated interferon plus ribavirin. The 25(OH)D serum levels were measured by high-pressure liquid chromatography. Tissue expression of cytochrome (CY) P27A1 and CYP2R1, liver 25-hydroxylating enzymes, were as…

AdultLiver CirrhosisMaleVITAMIN D CHRONIC HEPATITIS Cmedicine.medical_specialtyGenotypeCombination therapyHepacivirusSettore MED/08 - Anatomia PatologicaGastroenterologychemistry.chemical_compoundBlood serumRisk FactorsPegylated interferonInternal medicineRibavirinmedicineVitamin D and neurologyHumansVitamin DCytochrome P450 Family 2AgedSettore MED/12 - GastroenterologiaHepatologybusiness.industryRibavirinHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasechemistryImmunologyCholestanetriol 26-MonooxygenaseFemaleInterferonsSteatosisbusinessViral hepatitismedicine.drug
researchProduct

Effects of photodynamic therapy in periodontal treatment: A randomized, controlled clinical trial

2017

Aim To evaluate the effects of photodynamic therapy (PDT) in the nonsurgical treatment of chronic periodontitis. Materials and methods A randomized, single-blind, controlled, parallel-group clinical trial was performed. Sixty patients were enrolled: 20 healthy controls and 40 patients with periodontitis. The 40 patients were randomized for scaling and root planing (SRP) or SRP+PDT. Periodontal (plaque index, probing depth, clinical recession, clinical attachment level, bleeding on probing, and gingival crevicular fluid volume, corresponding to 381 vs 428 critical sites), microbiological (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema dentico…

AdultMale0301 basic medicine030103 biophysicsmedicine.medical_specialtyBleeding on probingDentistryenvironment and public healthGastroenterologyRoot Planing03 medical and health sciences0302 clinical medicineScaling and root planingInternal medicinemedicineHumansTannerella forsythiaSingle-Blind MethodAgedPeriodontitisbiologybusiness.industryPrevotella intermediaAggregatibacter actinomycetemcomitansCampylobacter rectus030206 dentistryMiddle Agedbiology.organism_classificationmedicine.diseaseChronic periodontitisTreatment OutcomePhotochemotherapyChronic PeriodontitisDental ScalingPeriodonticsFemalePeriodontal Indexmedicine.symptombusinessBiomarkersJournal of Clinical Periodontology
researchProduct

A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with…

2017

Here we report the applicability of a protocol based on clinical conditions and risk factors (RFs) for managing 35 allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients who developed a total of 52 episodes of respiratory viral infections (RVIs) caused by respiratory syncytial virus (RSV; n=19), human parainfluenza virus (HPIV; n=29), or both (n=4) over a 2-year study period. Risk categories were classified as high risk (cat-1) when the immunodeficiency scoring index was >= 3 and/or >= 3 RFs and/or >= 1 co-infective virus(es) were present; the remaining cases were classified as low risk (cat-0). The presence of two or more signs or symptoms including fever (T>38 degrees C…

AdultMale0301 basic medicinemedicine.medical_specialtyrespiratory syncytial virus030106 microbiologyTonsillitisAdministration OralPilot ProjectsRespiratory Syncytial Virus InfectionsAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineLower respiratory tract infectionRibavirinmedicineHumansECIL-4allogeneic hematopoietic stem cell transplantationhuman parainfluenza virusProspective Studiesrespiratory viral infectionSinusitisimmunodeficiency scoring indexImmunodeficiencyAgedTransplantationParamyxoviridae InfectionsRespiratory tract infectionsbusiness.industryRibavirinHematopoietic Stem Cell TransplantationMiddle Agedmedicine.diseaseTransplantationHuman Parainfluenza VirusInfectious DiseaseschemistryImmunologyoral ribavirinFemalebusinessStem Cell Transplantation030215 immunology
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

2012

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-…

AdultMaleAdolescentInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultSex FactorsRibaviringenderHumansAgedSettore MED/12 - GastroenterologiaPeg IFNAge FactorsInterferon-alphaHepatitis C ChronicMiddle Agedcentral fat distribution cytokines metabolic syndrome pharmacokinetics sustained virological responseRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemaleEpatite HCV; Peg IFN; genderMenopauseSettore SECS-S/01 - StatisticaEpatite HCVJournal of viral hepatitis
researchProduct

Oxidative Stress Parameters in Saliva and Its Association with Periodontal Disease and Types of Bacteria

2015

Objective. To determine the association between oxidative stress parameters with periodontal disease, bleeding, and the presence of different periodontal bacteria.Methods. A cross-sectional study in a sample of eighty-six patients, divided into three groups depending on their periodontal status. Thirty-three with chronic periodontitis, sixteen with gingivitis, and thirty-seven with periodontal healthy as control. Oxidative stress biomarkers (8-OHdG and MDA), total antioxidant capacity (TAOC), and the activity of two antioxidant enzymes (GPx and SOD) were determined in saliva. Subgingival plaque samples were obtained from the deepest periodontal pocket and PCR was used to determine the prese…

AdultMaleArticle SubjectGingival and periodontal pocketClinical BiochemistryMicrobiologyGingivitisMalondialdehydeGeneticsmedicineTannerella forsythiaHumansPeriodontitisSalivaMolecular BiologyPorphyromonas gingivalisPeriodontitislcsh:R5-920Glutathione Peroxidasebiologybusiness.industrySuperoxide DismutaseMicrobiotaBiochemistry (medical)Aggregatibacter actinomycetemcomitansDeoxyguanosineTreponema denticolaGeneral Medicinemedicine.diseasebiology.organism_classificationChronic periodontitisOxidative Stress8-Hydroxy-2'-DeoxyguanosineCase-Control StudiesFemalemedicine.symptomlcsh:Medicine (General)businessBiomarkersResearch ArticleDisease Markers
researchProduct